Patents by Inventor John E. Leet

John E. Leet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cytotoxic xanthone compounds
    Patent number: 8263644
    Abstract: The present invention relates to xanthone compounds isolated from the plant Psorospermum molluscum Hochr. (Clusiaceae), a Madagascar plant, which are potent cytotoxic agents.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: September 11, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: John E. Leet, Craig R. Fairchild, Stephen W. Mamber, Xiaohong Liu
  • Inhibitors of HCV replication
    Patent number: 8143288
    Abstract: Compounds having the structure of formula I are described. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular can inhibit the function of the HCV NS5A protein.
    Type: Grant
    Filed: June 5, 2006
    Date of Patent: March 27, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Serrano-Wu, Makonen Belema, Lawrence B. Snyder, Nicholas A. Meanwell, Denis R. St. Laurent, Ramesh Kakarla, Van N. Nguyen, Yuping Qiu, Xuejie Yang, John E. Leet, Min Gao, Donald R. O'Boyle, II, Julie A. Lemm, Fukang Yang
  • CYTOTOXIC XANTHONE COMPOUNDS
    Publication number: 20100311826
    Abstract: The present invention relates to xanthone compounds isolated from the plant Psorospermum molluscum Hochr. (Clusiaceae), a Madagascar plant, which are potent cytotoxic agents.
    Type: Application
    Filed: September 11, 2008
    Publication date: December 9, 2010
    Inventors: John E. Leet, Craig R. Fairchild, Stephen W. Mamber, Xiaohong Liu
  • Halo- or hydroxy-substituted nocathiacin antibiotics
    Patent number: 6287827
    Abstract: Fermentation of Nocardia sp. ATCC-202099 in the presence of a halogen- or hydroxy-substituted tryptophan precursor yields a novel corresponding halogen- or hydroxy-substituted nocathiacin compound which has broad spectrum antibiotic activity against Gram-positive bacteria and has in vivo efficacy in animals.
    Type: Grant
    Filed: May 1, 2000
    Date of Patent: September 11, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wenying Li, John E. Leet, Kin S. Lam
  • Nocathiacin antibiotics
    Patent number: 6218398
    Abstract: Novel thiazolyl peptide antibiotic compounds, including nocathiacin I, II and III, are disclosed. Also, novel microorganism ATCC-202099 is disclosed.
    Type: Grant
    Filed: July 13, 1999
    Date of Patent: April 17, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: John E. Leet, Helen A. Ax, Donald R. Gustavson, Daniel M. Brown, Laura Turner, Kimberly Brown, Wenying Li, Kin S. Lam
  • Ascosteroside and analogs thereof useful in antifungal compositions for methods of treating infections and inhibition of fungal growth
    Patent number: 5521169
    Abstract: Ascosteroside, obtainable by cultivation of a strain of Ascotricha amphitricha A.T.C.C. No. 74237, analogs thereof and salts and prodrugs of these compounds. The compounds have antifungal activity for use in a method for treating and preventing a fungal infection. Further, the compounds are useful in a method for inhibiting fungal growth.
    Type: Grant
    Filed: January 14, 1994
    Date of Patent: May 28, 1996
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jessica A. Gorman, Joseph O'Sullivan, John E. Leet, Stephen W. Mamber
  • Kedarcidin antitumor chromophore and pharmaceutical composition containing same
    Patent number: 5143906
    Abstract: Kedarcidin chromophore, a non-protein chromophore isolated from kedarcidin antitumor antibiotic, is obtained from purified or partially purified kedarcidin by solvent extraction and chromatographic procedures. The chromophore is characterized and found to contain substantially all of the antitumor activity of kedarcidin.
    Type: Grant
    Filed: September 26, 1991
    Date of Patent: September 1, 1992
    Assignee: Bristol-Myers Squibb Company
    Inventor: John E. Leet
  • BMY-40800 antitumor antibiotics
    Patent number: 5036010
    Abstract: A new antitumor antibiotic designated BMY-40800 is produced by fermentation of Streptomyces hygroscopicus ATCC 53653. The new compound inhibits the growth of tumors in experimental animals.
    Type: Grant
    Filed: April 26, 1990
    Date of Patent: July 30, 1991
    Assignee: Bristol-Myers Company
    Inventors: King S. Lam, Jacqueline Mattei, John E. Leet, James A. Matson, Koji Tomita, Murray A. Kaplan
  • BMY-40800 antitumor antibiotics
    Patent number: 4994271
    Abstract: A new antitumor antibiotic designated BMY-40800 is produced by fermentation of Streptomyces hygroscopicus ATCC 53653. The new compound inhibits the growth of tumors in experimental animals.
    Type: Grant
    Filed: February 16, 1988
    Date of Patent: February 19, 1991
    Assignee: Bristol-Myers Company
    Inventors: Kin S. Lam, Jacqueline Mattei, John E. Leet, James A. Matson, Koji Tomita, Murray A. Kaplan
  • Compositions of matter and methods of using same
    Patent number: 4833257
    Abstract: New and exceptionally potent antineoplastic agents denominated Bryostatin 9, Bryostatin 10, Bryostatin 11, Bryostatin 12 and Bryostatin 13 have been isolated from the marine animal Bugula neritina (Linneaeus) (Bryozoan phylum) and the structures identified. Meaningful antineoplastic activity is found for each.
    Type: Grant
    Filed: July 28, 1986
    Date of Patent: May 23, 1989
    Assignee: Arizona Board of Regents
    Inventors: George R. Pettit, Cherry L. Herald, Yoshiaki Kamano, John E. Leet